Compare DRD & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DRD | EWTX |
|---|---|---|
| Founded | 1895 | 2017 |
| Country | South Africa | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.5B |
| IPO Year | N/A | 2021 |
| Metric | DRD | EWTX |
|---|---|---|
| Price | $30.93 | $24.64 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 8 |
| Target Price | $27.50 | ★ $34.13 |
| AVG Volume (30 Days) | 410.2K | ★ 1.8M |
| Earning Date | 02-18-2026 | 11-06-2025 |
| Dividend Yield | ★ 1.54% | N/A |
| EPS Growth | ★ 68.66 | N/A |
| EPS | ★ 1.46 | N/A |
| Revenue | ★ $443,674,785.00 | N/A |
| Revenue This Year | $18.10 | N/A |
| Revenue Next Year | $25.92 | N/A |
| P/E Ratio | $21.42 | ★ N/A |
| Revenue Growth | ★ 26.26 | N/A |
| 52 Week Low | $8.38 | $10.60 |
| 52 Week High | $34.80 | $30.48 |
| Indicator | DRD | EWTX |
|---|---|---|
| Relative Strength Index (RSI) | 52.19 | 54.70 |
| Support Level | $30.23 | $23.95 |
| Resistance Level | $34.80 | $27.40 |
| Average True Range (ATR) | 1.36 | 2.31 |
| MACD | -0.16 | 0.01 |
| Stochastic Oscillator | 27.41 | 65.84 |
DRDGold Ltd is a South African gold mining company engaged in surface gold tailings retreatment including exploration, extraction, processing, and smelting. Its reportable operating segments are; Ergo, FWGR, and Corporate office and other reconciling items. The Ergo is a surface gold retreatment operation that treats old slime dams and sand dumps to the south of Johannesburg's central business district as well as the East and Central Rand goldfields, and the FWGR which is a surface gold retreatment operation and treats old slime dams in the West Rand goldfields. The Ergo segment derives a vast majority of the company's revenue.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.